This framework explains the particularly aggressive clinical behaviour and immune-checkpoint-blockade resistance of CMS4 tumours, and highlights COL10A1+Fib as a tractable stromal target for overcoming the immune-refractory nature of this subtype. This evidence concerns the gene COL10A1 and neoplasm.